Immunotherapy Clinical Trials offered for Acute Myelogenous Leukemia

A Study of Daunorubicin and Gemtuzumab-Ozogamicin Therapies to Treat Adult Acute Myeloid Leukemia.
This trial is being performed by the Mayo Clinic and has no age restrictions and is investigating which immunotherapy treatment, Daunorubicin or Gemtuzumab-Ozogamicin, works best for AML when joined with stem cell treatment as well as chemotherapy. It is located in Rochester, MN, Jacksonville, FL, Scottsdale, AZ, and Phoenix, AZ. READ MORE

Phase II Randomized Study of Idarubicin and Cytarabine With or Without Bevacizumab in Patients With Newly Diagnosed Acute Myeloid Leukemia.
This trial is investigating the differences between immunotherapy along with chemotherapy compared to chemotherapy alone for AML patients who are up to 59 years old. This trial is located at the MD Anderson Cancer Center in Houston, TX. READ MORE

Phase II Pilot Study of Gemtuzumab Oxogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy.
This phase II trial is for children (between 1 month and 21 years old) recently diagnosed with AML who have never had antileukemia therapy. This trial will test the effectiveness of the drug gemtuzumab ozogamicin in conjunction with chemotherapy and bone marrow transplantation for newly diagnosed Acute Myeloid Leukemia patients. This trial is located in every state except AK and WY. READ MORE

Phase I Evaluation of the Anti-CD33 Immunotoxin Hum-195/rGel in Patients with Advanced Myeloid Malignancies.
AML patients who are at least 18 years old and have not responded to chemotherapy treatment in the past are eligible to be treated with an immunotoxin drug being investigated in this trial. This study is located at the MD Anderson Cancer Center in Houston, TX. READ MORE

A Dose-Finding study of the safety of Gemtuzumab Zogamicin as single agent treatment of patients with relapsed Acute Myelogenous Leukemia after autologous or allogenic Hematopoietic Stem Cell Transplant (HSCT).
T his trial has no age or gender restrictions and is evaluating the safety and effectiveness of a new immunotherapy antibody treatment for AML. This trial is located in AR, CT, FL, HI, KS, NJ, NY, OH, TX, WV, and WI. READ MORE

A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose Ara-C for Patients with Relapsed Acute Myeloid Leukemia (AML).
This trial is located in Duarte, CA at the City of Hope National Medical Center. This trial will focus on using immunotherapy techniques along with chemotherapy drugs to prevent further relapse of AML in patients. This trial is located at the City of Hope National Medical Center in Duarte, CA. READ MORE

Phase II Study of Gemtuzumab Ozogamicin and Cytarabine in Patients With Relapsed Acute Myeloid Leukemia.
This trial will combine immunotherapy and chemotherapy techniques to treat patients who are at least 18 years old and have been diagnosed with AML. This trial is located in AL, AZ, AK, CA, CO, DC, FL, GA, HI, IL, KS, KY, LA, MA, MI, MS, MO, MT, NM, NY, NC, OH, OK, OR, SC, TN, TX, UT, and WA. READ MORE

Phase III Randomized Study of Induction Therapy Comprising Cytarabine and Daunorubicin With Versus Without Gemtuzumab Ozogamicin Followed By Consolidation Therapy Comprising High-Dose Cytarabine and Post-Consolidation Therapy Comprising Gemtuzumab Ozogamicin Versus No Additional Therapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia.
This trial will be comparing two different regimens of immunotherapy and chemotherapy for AML patients who are between 18 and 55 years old. This trial is located in AL, AZ, AK, CA, DC, FL, GA, HI, IL, KS, KY, LA, MA, MI, MS, MO, MT, NM, NY, NC, OH, OK OR, SC, TN, TX, UT, and WA. READ MORE

Phase I Study of Gemtuzumab Ozogamicin in Combination With Conventional Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes.
This trial is combining immunotherapy and chemotherapy for treating AML patients under 21 years old. This trial is located in AR, CA, DC, FL, GA, IL, IN, MD, MA, MI, MN, MS, MO, NJ, NY, NC, OH, OR, PA, SC, TN, TX, WA, and WI. READ MORE

Phase I Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Persistent or Progressive Malignancies.
This trial is investigating how effective monoclonal antibody therapy is when combined with stem cell transplantation for AML patients between 14-71 years old. This trial is located at the UCSD Cancer Center in La Jolla, CA and at the Scripps Cancer Center in La Jolla, CA. READ MORE

Phase I Study of Alemtuzumab, Low-Dose Total Body Irradiation, and Fludarabine Followed By HLA Class I Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies.
AML patients up to 74 years old will be eligible to receive immunotherapy, radiation, and chemotherapy treatment followed by peripheral stem cell transplantation. This trial is located in CA, CO, TX, UT, WA, and WI. READ MORE

Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Gemtuzumab Ozogamicin Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia.
AML patients between the ages of 16 and 60 are eligible. The trial will test the difference between the combination of chemotherapy, immunotherapy, and stem cell transplantation versus the combination of chemotherapy and stem cell transplantation to treat AML. This trial is located in AL, AZ, CO, FL, IL, MA, MI, MN, NJ, NY, ND, PA, SD, TN, and WI. READ MORE

Phase I Pilot Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-CTLA4) in Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Non-Small Cell Lung Cancer Previously Treated With Sargramostim (GM-CSF)-Based Autologous Tumor Vaccine.
AML patients who are at least 18 years old may participate in this trial that is studying the effectiveness of a new monoclonal antibody treatment for AML and other cancers. This trial is located at the Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute in Boston, MA. READ MORE

Phase II Study of Monoclonal Antibody HuG1-M195, Arsenic Trioxide, Idarubicin, and Tretinoin in Patients With Acute Promyelocytic Leukemia in Clinical Complete Remission Following Tretinoin-Based Induction Therapy.
There are no age or gender restrictions for this trial, which is studying the effectiveness of a new monoclonal antibody treatment for AML. This trial is located at the Memorial Sloan-Kettering Cancer Center in New York City, NY. READ MORE

Phase I/II Study of Bismuth Bi 213 Monoclonal Antibody M195 and Cytarabine in Patients With Advanced Myeloid Malignancies.
There are no age restriction for this trial, which is studying how effectively a new antibody can treat AML when used with chemotherapy drugs. This trial is located at the Memorial Sloan-Kettering Cancer Center in New York City, NY. READ MORE

Phase I Study of Adoptive Immunotherapy Comprising CD8-Positive Minor Histocompatability Antigen-Specific Cytotoxic T-Lymphocytes in Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation.
AML patients who are at least 14 years old may participate in this trial which is studying the side effects of a specific kind of immunotherapy technique used for cancer. This trial is located at the Fred Hutchinson Cancer Research Center in Seattle, WA. READ MORE

Phase I Study of Iodine I 131 Monoclonal Antibody BC8 With Low-Dose Total Body Irradiation, Allogeneic Peripheral Blood Stem Cell Infusion, and Immunosuppression With Cyclosporine and Mycophenolate Mofetil in Elderly Patients With Advanced Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, or Chronic Myelomonocytic Leukemia.
AML patients who are at least 50 years old may participate in this trial which is studying the effectiveness of combining a new antibody treatment with radiation, chemotherapy, and stem cell transplantation for AML patients. This trial is located at the Fred Hutchinson Cancer Research Center in Seattle, WA. READ MORE

Sources

ClinicalTrials.gov, www.clinicaltrials.gov

Center Watch—Clinical Trials Listing Service, http://www.centerwatch.com/patient/studies/cat92.html

UCLA Health Sciences, http://www.cancer.mednet

Mayo Clinic, http://clinicaltrials.mayo.edu/